Drug profiles discussed in this report include flubendazole
, IIC-942A001, IIC-950A001, lymphatic filariasis vaccine, S-011-2091, S-0112094, Small Molecule for Elephantiasis, Small Molecule for Lymphatic Filariasis, Small Molecules for Lymphatic Filariasis and Onchocerciasis and Small Molecules for Nematodal Diseases and Tuberculosis.
: Janssen entered into a non-exclusive, royalty-free preclinical data sharing agreement with the not-for-profit Drugs for Neglected Diseases initiative (DNDi) for the preclinical research of a reformulated form of flubendazole
, a potential new treatment against parasites that cause lymphatic filariasis (elephantiasis) and onchocerciasis (river blindness), two of the most difficult-to-treat neglected tropical diseases.
Johnson & Johnson will work with its partners on pre-clinical research and clinical development of flubendazole, a potential new treatment against parasites that cause lymphatic filariasis (elephantiasis) and onchocerciasis (river blindness), two debilitating diseases for which current treatments do not eradicate the parasites.
Unlike drugs that are currently used to treat parasitic infections affecting the skin or the eyes, flubendazole has an important advantage: it kills adult parasites rather than just their larvae.
Working in collaboration with other pharmaceutical partners, Johnson & Johnson will contribute scientific, supply assistance and technical expertise to Drugs for Neglected Diseases initiative(DNDi) to reformulate flubendazole to enhance its bioavailability in blood and tissues and conduct pre-clinical testing.